A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT, WITHOUT TYPE 2 DIABETES (ENLIGHTEN-1)

Intervention/treatment:
ELORALINTIDE (LY3841136)
Medical condition:
OBESITY
Protocol code:
J3R-MC-YDAG
Control number:
305917
Status:
Recruiting
Approved:
February 24, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07321886
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
1-317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Aggarwal and Associates Limited
Brampton, L6T 0G1
RECRUITING
Role
CONTACT
Phone:
9054589033
Name
Naresh Aggarwal
Role
PRINCIPAL_INVESTIGATOR
Alpha Recherche Clinique
Québec, G2J 0C4
RECRUITING
Role
CONTACT
Phone:
418-704-1112
Name
Anne-Marie Beaulieu
Role
PRINCIPAL_INVESTIGATOR
ALPHA Recherche Clinique
Québec, G3K 2P8
RECRUITING
Role
CONTACT
Phone:
418-847-1112
Name
Maggie Lévesque
Role
PRINCIPAL_INVESTIGATOR
Bluewater Clinical Research Group Inc.
Sarnia, N7T 4X3
RECRUITING
Role
CONTACT
Phone:
1 (519) 344-6612
Name
John O'Mahony
Role
PRINCIPAL_INVESTIGATOR
Dawson Clinical Research Inc.
Guelph, N1H 1B1
RECRUITING
Role
CONTACT
Phone:
519-222-8251
Name
Garry Wallace
Role
PRINCIPAL_INVESTIGATOR
Diex Recherche Inc. Division Trois-Rivieres
Trois-Rivières, G9A 4P3
RECRUITING
Name
Jean-francois Naud
Role
PRINCIPAL_INVESTIGATOR
Med Trust Research
Courtice, L1E 2J5
RECRUITING
Name
Anojan Kathirkamanayagan
Role
CONTACT
Phone:
905-728-7915 ext. 5
Name
Anojan Kathirkamanayagan
Role
PRINCIPAL_INVESTIGATOR
The Wharton Medical Clinic Clinical Trials Inc
Hamilton, L8L 5G8
RECRUITING
Role
CONTACT
Phone:
9055238134 x 274
Name
Mateen Akhtar
Role
PRINCIPAL_INVESTIGATOR
Winterberry Research Inc.
Hamilton, L8J 0B6
RECRUITING
Role
CONTACT
Phone:
365-366-6267
Name
Steven Zizzo
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources